Icatibant Medical Valley

Icatibant, the active ingredient in Icatibant Medical Valley, is a bradykinin B2 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed HAE. GNH USA supplies Icatibant Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema. - Hereditary angioedema (HAE) acute attacks: rapidly reduces edema and associated pain by blocking bradykinin‑mediated vascular permeability.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema or edema. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or airway: worsening swelling that could compromise breathing. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases.

Before using Icatibant, consider the following safety measures. - Hypersensitivity: avoid if the patient has known allergy to icatibant or any excipients. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: weigh benefits against possible effects on the infant. - Concomitant bradykinin‑modulating drugs: monitor for additive effects on blood pressure. - Renal or hepatic impairment: adjust monitoring as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - ACE inhibitors: combined use may increase risk of angioedema. - Angiotensin receptor blockers (ARBs): may potentiate bradykinin‑related swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may affect HAE severity. - Other subcutaneous biologics: monitor injection site reactions. - Diuretics: observe for blood pressure changes. - NSAIDs: watch for additive edema risk.